on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has published a Form 8.3 filing, revealing its position in Avadel Pharmaceuticals plc. This disclosure, mandated by the Irish Takeover Panel, shows interests in relevant securities representing 1% or more. Specifically, Vanguard holds 5,865,286 ordinary shares, equating to a 6.02% stake in Avadel. These shares have a nominal value of US$0.01 each.
The filing reports recent transactions, with a purchase of 686 shares at $21.59 each and a sale of 133 shares at the same price. Vanguard indicates no engagement in derivative agreements or other formal arrangements related to Avadel's securities. Additionally, the filing states there are no indemnities, options, or voting agreements impacting these securities. The disclosure reflects activity as of December 26, 2025.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news